IV Infusion

Sponsor worked with Frontage on BE/BA study using IV infusion. The product was approved in tablet form however the sponsor was looking to convert the drug into an injectable liquid as a quick on set for the treatment of severe migraines.

"*" indicates required fields

First Name*

Last Name*

Company*

State*

Country

Email*

Phone*

Please only hit the submit button once.

I AGREE*

By submitting this form I agree that Frontage may process my data in the manner described in Frontage’s Privacy Policy.

Comments

This field is for validation purposes and should be left unchanged.

IV Infusion

Resources to Consider

Cost Effective and Efficient Progression of Lead Drug Candidates to...

Development of Stable Nanoemulsion Formulation as an Ophthalmic Drug...

A Competitive Ligand-binding Assay for the Detection of Neutralizing...

Validation of a 384 gene hybridization capture-based pharmacogenomics...

Validation of Ultra-high Sensitive SIMOA Assays for the Quantitation...

Quantitative Whole-Body Autoradiography (QWBA) and Radiation...

GeneTox: A Pivotal Part of Safety Assessment

Guidelines for Developmental and Reproductive Toxicity (DART) Testing

Biomarker and Alzheimer’s disease: role of high sensitivity...

Relative Bioavailability Study of Colchicine Oral Solution and...

BSEPcyte® and MDR3cyte®: Innovative Solutions for Investigating...

First to File Bioequivalency